Compare NOG & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | ADPT |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2000 | 2019 |
| Metric | NOG | ADPT |
|---|---|---|
| Price | $21.48 | $17.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $31.14 | $17.78 |
| AVG Volume (30 Days) | ★ 2.6M | 1.7M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.44% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,475,723,000.00 | $276,976,000.00 |
| Revenue This Year | $14.07 | $3.98 |
| Revenue Next Year | $4.24 | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 11.23 | ★ 54.77 |
| 52 Week Low | $20.18 | $9.96 |
| 52 Week High | $32.62 | $20.76 |
| Indicator | NOG | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 66.43 |
| Support Level | $21.41 | $14.87 |
| Resistance Level | $22.86 | $17.52 |
| Average True Range (ATR) | 0.72 | 0.93 |
| MACD | -0.01 | 0.33 |
| Stochastic Oscillator | 22.52 | 81.33 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.